Members Login
Channels
Special Offers & Promotions
'Lab Time Share
publication date: Aug 9, 2011
|
author/source: Medilink Yorkshire & Humber
A new concept in the pharmaceutical field -
'Lab Time Share', which provides companies with flexible ways to access
expertise, lab space, high end equipment and qualified staff, has been
developed by Yorkshire based Agenda 1 Analytical Services.
Lab Time Share provides a new way to support start up pharmaceutical business as well as global organisations, by ensuring a company's investment is spent on what's most important - developing new products and technology.
Kuecept, a drug development company from Potter's Bar, uses Agenda1's facilities to apply new drug delivery technology to help clients progress their products into clinic, working with applications such as nano-particles, amorphous materials and drug solubisation technologies.
Speaking about working alongside Agenda1, Dr Mark Saunders - Development Director at Kuecept, said:
"Setting up dedicated lab space is very time consuming and comes with significant overheads. This can often be a rate limiting step for anyone wanting to set up a new laboratory based business. Initially the Lab Time Share scheme provided Kuecept with a fast route to market, allowing us to focus our efforts on our core business needs whilst still providing a top-class service to our clients."
Available to organisations of all sizes, from university spin outs to global pharmaceutical companies, the service allows customers to have as much or little direct control over their processes as they desire, ensuring the approach remains flexible and cost efficient.
Agenda 1 also have a number of segregated lab facilities, which means that it is practical to isolate processes and workers where required, often an important element in analytical testing labs.
Managing Director of Agenda 1, Ian Siragher, said: "Our aim is to facilitate the pharmaceutical process in whatever way works for our customers, whether this be working alongside development scientists or engineers or handling the entire process ourselves, we can swiftly and accurately provide the appropriate data required and guide a company to the next level."
For more information visit medilink.co.uk
Lab Time Share provides a new way to support start up pharmaceutical business as well as global organisations, by ensuring a company's investment is spent on what's most important - developing new products and technology.
Kuecept, a drug development company from Potter's Bar, uses Agenda1's facilities to apply new drug delivery technology to help clients progress their products into clinic, working with applications such as nano-particles, amorphous materials and drug solubisation technologies.
Speaking about working alongside Agenda1, Dr Mark Saunders - Development Director at Kuecept, said:
"Setting up dedicated lab space is very time consuming and comes with significant overheads. This can often be a rate limiting step for anyone wanting to set up a new laboratory based business. Initially the Lab Time Share scheme provided Kuecept with a fast route to market, allowing us to focus our efforts on our core business needs whilst still providing a top-class service to our clients."
Available to organisations of all sizes, from university spin outs to global pharmaceutical companies, the service allows customers to have as much or little direct control over their processes as they desire, ensuring the approach remains flexible and cost efficient.
Agenda 1 also have a number of segregated lab facilities, which means that it is practical to isolate processes and workers where required, often an important element in analytical testing labs.
Managing Director of Agenda 1, Ian Siragher, said: "Our aim is to facilitate the pharmaceutical process in whatever way works for our customers, whether this be working alongside development scientists or engineers or handling the entire process ourselves, we can swiftly and accurately provide the appropriate data required and guide a company to the next level."
For more information visit medilink.co.uk
Media Partners